Violet, sometimes called purple, is the awareness ribbon color most widely associated with Hodgkin’s lymphoma. You will also encounter lime green used broadly for all lymphomas, including Hodgkin’s, depending on which advocacy group or campaign is involved. The overlap exists because awareness ribbon assignments are not centrally governed, and different organizations have adopted slightly different palettes. Beyond the ribbon itself, the disease it represents has a distinctive biology and an unusually young patient population, and the story of survivorship after treatment carries its own set of concerns worth understanding.
Why More Than One Color Shows Up
Awareness ribbons lack a single regulating authority. Organizations choose colors independently, which means the same disease sometimes gets represented by more than one ribbon depending on who is running the campaign. For Hodgkin’s lymphoma, violet is the most commonly cited disease-specific color. But the Lymphoma Research Foundation and similar groups use lime green as a blanket color for lymphoma awareness overall, covering both Hodgkin’s and non-Hodgkin’s subtypes under one symbol. Meanwhile, the Leukemia & Lymphoma Society, one of the largest blood cancer organizations in the world, uses orange to represent all blood cancers together, including leukemia, lymphoma, and myeloma.
If you are choosing a ribbon for a fundraiser, walk, or social media post specifically about Hodgkin’s lymphoma, violet is the most targeted choice. Lime green works when the message is about lymphoma more broadly. And orange signals solidarity with the entire blood cancer community. None of these is wrong, they just reflect different levels of specificity.
Awareness Months and Campaigns
September is recognized as both Blood Cancer Awareness Month and Lymphoma Awareness Month in the United States. During September, advocacy organizations concentrate their public education efforts, fundraising drives, and media outreach around lymphoma and related blood cancers. The Leukemia & Lymphoma Society, founded in 1949, has been a central player in these campaigns, with a mission focused on curing leukemia, lymphoma, Hodgkin’s disease, and myeloma while supporting patients and families.1Cancer Research. Relentless in the fight against blood cancer: the Leukemia & Lymphoma Society The organization reported making over seven million contacts with patients, caregivers, and healthcare professionals in a single fiscal year and maintains a network of tens of thousands of advocacy volunteers across the country.
World Lymphoma Awareness Day falls on September 15 each year and is coordinated by the Lymphoma Coalition, an international network of patient groups. The day is specifically designed to draw attention to symptoms, promote early diagnosis, and remind survivors about long-term follow-up care. If you see violet or lime green ribbons in mid-September, that is the likely context.
What Makes Hodgkin’s Lymphoma Different from Other Lymphomas
The term “lymphoma” covers a large family of cancers that start in the lymphatic system. The major split is between Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, and while they share a name and an organ system, they behave quite differently. Hodgkin’s lymphoma is defined by the presence of distinctive oversized cells called Hodgkin and Reed-Sternberg cells, which are large, often have more than one nucleus, and look unlike any normal cell in the body.2PubMed. The Hodgkin and Reed/Sternberg cell These cells are the actual tumor cells, even though they make up only a small fraction of the tissue in an affected lymph node. The bulk of the tumor mass is composed of surrounding immune cells that have been recruited and manipulated by the cancer.
In nearly all cases, Reed-Sternberg cells originate from a type of immune cell called a B cell. Specifically, the pattern of genetic mutations in these cells suggests they come from B cells that were supposed to die during a normal immune process but somehow survived and became malignant.2PubMed. The Hodgkin and Reed/Sternberg cell Non-Hodgkin’s lymphoma, by contrast, encompasses dozens of subtypes with very different cell origins, growth patterns, and prognoses. The presence of Reed-Sternberg cells is specific enough that it serves as the hallmark for confirming a Hodgkin’s diagnosis.3PubMed Central. Hodgkin Reed-Sternberg-Like Cells in Non-Hodgkin Lymphoma
Who Gets Hodgkin’s Lymphoma
One of the more distinctive features of Hodgkin’s lymphoma is its age pattern. Unlike most cancers, which climb steadily with age, Hodgkin’s follows a two-peak distribution. The first and larger peak hits young adults, roughly between 15 and 34, and the second peak appears in adults over 55.4PubMed. Hodgkin’s disease Global data confirm this bimodal pattern, with incidence peaking among those aged 20 to 39 and again in people 60 and older.5PubMed Central. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study This makes Hodgkin’s lymphoma one of the most common cancers among adolescents and young adults, a group that faces unique challenges because their care often falls between pediatric and adult medical systems.6PubMed. Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care
The fact that Hodgkin’s lymphoma so often strikes people in their twenties and thirties is part of what gives the violet ribbon its emotional weight. These are people at the start of careers, relationships, and families. It also means survivorship concerns stretch across many decades, which raises the stakes around late effects of treatment in ways that are less pressing for cancers diagnosed primarily in the elderly.
The Epstein-Barr Virus Connection
Roughly 30 to 50 percent of Hodgkin’s lymphoma cases are associated with the Epstein-Barr virus, the same virus that causes mononucleosis.7PubMed. Epstein-Barr virus-associated Hodgkin’s lymphoma In these cases, viral DNA is found directly inside the Reed-Sternberg cells, and the virus is not just a bystander. It produces proteins that help reprogram the infected cells, contributing to the abnormal behavior that defines the cancer.8PubMed Central. EBV in Hodgkin Lymphoma
The virus’s involvement is not evenly distributed. EBV-positive Hodgkin’s lymphoma is more common in children, in older adults, in males, and in developing countries. The young-adult form of the disease seen in industrialized countries, which tends to have a particular tissue pattern called nodular sclerosis, is typically EBV-negative.8PubMed Central. EBV in Hodgkin Lymphoma This split suggests that the two age peaks in the incidence curve may actually represent somewhat different diseases sharing a common cell type, with different triggers driving each peak. EBV-positive disease in elderly and immunosuppressed patients tends to carry a worse prognosis.7PubMed. Epstein-Barr virus-associated Hodgkin’s lymphoma
Treatment and the Rise of Checkpoint Inhibitors
Hodgkin’s lymphoma is one of the most curable cancers, with long-term survival rates that would have been unimaginable a few decades ago. Standard first-line treatment typically involves combination chemotherapy, sometimes with radiation. But the treatment landscape has shifted considerably with the introduction of immune checkpoint inhibitors, drugs that essentially remove a brake that cancer cells use to hide from the immune system.
The checkpoint inhibitors nivolumab and pembrolizumab were initially approved for patients whose Hodgkin’s lymphoma had relapsed multiple times after other treatments. They have since been incorporated into earlier lines of therapy. When combined with other agents like brentuximab vedotin or standard chemotherapy as a second-line approach, these drugs produce high rates of complete remission and durable disease control after stem cell transplant.9PubMed Central. The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma Researchers are now testing whether adding checkpoint inhibitors to frontline treatment can improve outcomes even further, with early results from a Phase III trial of nivolumab combined with standard chemotherapy comparing favorably against the current standard of care for advanced-stage disease.9PubMed Central. The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma
The high cure rates are a major reason awareness campaigns for Hodgkin’s lymphoma focus not only on diagnosis but also on the quality of life after treatment. Curing the cancer is the starting point, not the finish line.
Why Survivorship Is a Central Part of Awareness
Because Hodgkin’s lymphoma is so often cured, many patients live for decades after treatment. That long survivorship window means late side effects have time to emerge, and some of them are serious. Second cancers and cardiovascular disease are the leading causes of death among long-term Hodgkin’s lymphoma survivors, who carry a two- to fourfold increased risk of developing these complications compared with the general population.10Hematology Am Soc Hematol Educ Program. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment Other late effects include thyroid problems, lung dysfunction, infertility, and persistent fatigue.
Heart failure is a particular concern. The risk rises with both radiation dose to the heart and exposure to certain chemotherapy drugs called anthracyclines. Among patients who received higher radiation doses and anthracycline-containing chemotherapy, the 25-year cumulative risk of heart failure reached roughly a third.11Blood. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines Data from a large survivorship cohort confirmed that higher radiation doses to the heart increased the risk of coronary artery disease and heart failure in a dose-dependent way, with each additional 10 gray of radiation increasing the risk of cardiac disease by about 40 percent.12JAMA Network Open. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children
This is why modern treatment protocols have been steadily reducing radiation fields and doses, and why research into checkpoint inhibitors is so important. If effective immunotherapy can replace some of the radiation or anthracycline exposure, the hope is that survivors decades from now will face fewer of these late-emerging threats. For current survivors, long-term cardiac monitoring and screening for second cancers are standard recommendations.
The Young Adult Experience
Hodgkin’s lymphoma sits squarely in what oncologists call the adolescent and young adult, or AYA, space. This is a population with distinct needs that do not always fit neatly into either pediatric or adult cancer care. A young person diagnosed at 22 may find themselves in an adult oncology clinic designed around patients twice their age, or they may be seen in a pediatric center that does not address the concerns of someone navigating college, employment, or new relationships during treatment.
Care for this group remains fragmented between the two systems, which contributes to variability in treatment approaches and survivorship outcomes.6PubMed. Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care Beyond the medical treatment itself, young adult survivors face specific psychosocial and financial burdens. Fertility preservation before treatment is a real and time-sensitive decision. Career disruptions during peak earning years can have long financial consequences. And the psychological weight of facing a life-threatening diagnosis at an age when peers are healthy can create lasting effects that standard follow-up care does not always address.
Awareness campaigns that use the violet ribbon often try to reach this demographic specifically, encouraging young people not to dismiss persistent symptoms like unexplained swollen lymph nodes, night sweats, unexplained weight loss, or persistent itching. Early-stage Hodgkin’s lymphoma responds exceptionally well to treatment, and delays in diagnosis are more common in young adults who assume they are too young for cancer.
Research Funding and What the Ribbon Represents
Awareness ribbons serve a practical function beyond symbolism. They anchor fundraising campaigns, and in the cancer research world, funding follows visibility. Between 2016 and 2020, global public and philanthropic investment in cancer research totaled about $24.5 billion, with breast cancer receiving the largest share at $2.7 billion and hematological cancers (a category that includes Hodgkin’s and non-Hodgkin’s lymphomas along with leukemias) receiving about $2.3 billion.13The Lancet Oncology. Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments Blood cancers collectively ranked second in total research investment, which reflects decades of advocacy by organizations like the Leukemia & Lymphoma Society and its network of patient advocates.14Cancer Research. Abstract ADV25: Relentless in the fight against blood cancer: The Leukemia & Lymphoma Society
The violet ribbon for Hodgkin’s lymphoma does not carry the same instant recognition as the pink ribbon for breast cancer, and that gap in visibility is something patient advocates are actively working to close. The pink ribbon’s cultural dominance has been both a model and a cautionary tale for other cancer communities. Researchers have documented how corporate use of the pink ribbon can sometimes obscure rather than advance the health message, a phenomenon sometimes called “pinkwashing.”15Social Responsibility Journal. From pink ribbons to pinkwashing: beneficiary-design fit and CSR authenticity Hodgkin’s lymphoma advocates have generally tried to keep their messaging more tightly connected to patient education and early detection rather than broad consumer marketing.
When You See a Violet Ribbon
If you spot a violet ribbon on someone’s lapel, on a social media profile, or at a fundraising event, it signals awareness of Hodgkin’s lymphoma specifically. A lime green ribbon broadens the message to all lymphomas. And an orange ribbon encompasses the full spectrum of blood cancers. All three colors share a common goal of driving attention toward diseases that, despite high cure rates in many cases, carry meaningful long-term consequences for survivors and continue to need research investment. The violet ribbon’s particular resonance comes from the fact that it often represents someone who was diagnosed young, treated aggressively, cured, and then left to navigate a decades-long survivorship journey that requires its own kind of vigilance.